SACITUZUMAB DROZUNTECAN
UNII ZK7CK72678

Substance Identification & Data

This profile provides standardized clinical and technical data for Sacituzumab Drozuntecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) ZK7CK72678.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2792722-58-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

ZK7CK72678

CAS Registry Number

2792722-58-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

SACITUZUMAB DROZUNTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C188363

National Cancer Institute reference terminology for clinical and research data.

INN ID

13710

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Sacituzumab Drozuntecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Sacituzumab Drozuntecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

H-gamma1 heavy chain (1-451) [humanized VH (Homo sapiens IGHV7-4-1*02 (85.7%) -(IGHD)-IGHJ4*01 (86.7) T122>S (115), CDR_IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14 (CH1 R120 (218) (122-219), hinge (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-9*01 (82.2%) -IGKJ4*01 (91.7%) G120>A (100), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01, Km3, A45.1 (153'), V101 (191') (108'-214')]; dimer (230-230":233-233")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of 4.5 L-cysteinyl residues on an average among 214', 214''', 224, 224'', 230, 230'', 233, 233'' with (3RS)-1-[(3S,11S)-11-benzyl-1-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino}-3-methyl-1,7,10,13,16,19-hexaoxo-4-oxa-6,9,12,15,18-pentaazatetracosan-24-yl]-2,5-dioxopyrrolidin-3-yl (drozuntecan) groups

Immunoglobulin G1, anti-(human tumor-associated calcium signal transducer 2) (human-Mus musculus monoclonal hRS7 heavy chain), disulfide with human-Mus musculus monoclonal hRS7 κ-chain, dimer, thioether with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[(1S)-3-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-3-oxopropoxy]methyl]glycinamide

Sacituzumab Drozuntecan

Sacituzumab drozuntecan [WHO-DD]

immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody; conjugated on an average of 4.5 cysteinyl residues to drozuntecan, comprising a cleavable linker and a camptothecin derivative (exatecan) (sacituzumab drozuntecan)

sacituzumab drozuntecan [INN]

External Clinical & Regulatory Resources

Previous UNIIZK6U5FTB5C

Next UNIIZK7JX4771P